"HLA-C Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Class I human histocompatibility (HLA) antigens encoded by a small cluster of structural genes at the C locus on chromosome 6. They have significantly lower immunogenicity than the HLA-A and -B determinants and are therefore of minor importance in donor/recipient crossmatching. Their primary role is their high-risk association with certain disease manifestations (e.g., spondylarthritis, psoriasis, multiple myeloma).
| Descriptor ID |
D015236
|
| MeSH Number(s) |
D12.776.395.550.489.600 D12.776.543.550.439.600 D23.050.301.500.100.600 D23.050.301.500.450.390 D23.050.705.552.100.600 D23.050.705.552.450.390
|
| Concept/Terms |
HLA-C Antigens- HLA-C Antigens
- HLA C Antigens
- HLA-C
- Antigens, HLA-C
- Antigens, HLA C
|
Below are MeSH descriptors whose meaning is more general than "HLA-C Antigens".
Below are MeSH descriptors whose meaning is more specific than "HLA-C Antigens".
This graph shows the total number of publications written about "HLA-C Antigens" by people in this website by year, and whether "HLA-C Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HLA-C Antigens" by people in Profiles.
-
Population Difference in Allele Frequency of HLA-C*05 and Its Correlation with COVID-19 Mortality. Viruses. 2020 11 20; 12(11).
-
Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017 Aug; 177(2):489-496.
-
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis. Mol Diagn Ther. 2016 06; 20(3):227-30.
-
Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1589-96.
-
Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood. 2014 Feb 20; 123(8):1270-8.
-
Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood. 2013 Nov 21; 122(22):3651-8.
-
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013 Aug; 169(2):458-63.
-
HLA-Cw*1202-B*5201-DRB1*1502 haplotype increases risk for ulcerative colitis but reduces risk for Crohn's disease. Gastroenterology. 2011 Sep; 141(3):864-871.e1-5.
-
HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jun; 17(6):885-92.
-
Coevolution of killer cell Ig-like receptors with HLA-C to become the major variable regulators of human NK cells. J Immunol. 2010 Oct 01; 185(7):4238-51.